The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A humanized monoclonal antibody directed against nerve growth factor (NGF), a modulator of nociceptor function, with potential analgesic activity. Tanezumab binds to NGF and prevents NGF binding to its high affinity, membrane-bound, catalytic receptor tropomyosin-related kinase A (TrkA), which is present on sympathetic and sensory neurons; reduced stimulation of TrkA by NGF inhibits the pain-transmission activities of these neurons. NGF, a neurotrophin, is critical to the growth and maintenance of sympathetic and sensory neurons. In addition, NGF may induce mast cells to release inflammatory proteins and may induce the upregulation of substance P and other pain-related peptides in sympathetic and sensory neurons. Upon neurotrophin binding, TrkA phosphorylates itself and members of the MAPK pathway, mediating the multiple neuronal effects of NGF. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonym:||anti-NGF monoclonal antibody RN624|
|Chemical structures:||Immunoglobulin G2, anti (human nerve growth factor) humanized mouse monoclonal N624 [Lys71,Ser330,Ser331]gamma 2 heavy chain (135-214')-disulfide with kappa light chain (223-23'':224-224'':227-227'':230-230'')-tetrakisdisulfide dimer |
immunoglobulin G2, anti (human nerve growth factor)(human mouse monoclonal N624 heavy chain), disulfide with human mouse monoclonal RN624 light chain, dimer